Arcturus Q4 2022 net income $117.3M ($4.33/diluted share), revenue surge to $160.3M on CSL deal

Arcturus Therapeutics Holdings Inc.

Q4 2022 revenue $160.3M vs $5.8M same quarter 2021; full-year revenue $206.0M vs $12.4M.
Recorded net income $117.3M ($4.33/diluted) for Q4 vs net loss $38.7M ($1.47 loss) prior year.
Received $200M upfront from CSL Seqirus in Dec 2022; $90M milestones invoiced in Mar 2023.
Cash $391.9M at Dec 31, 2022; repaid $17.1M to Singapore, eliminating $33.3M non-recourse debt.
ARCT-154 Phase 3 booster fully enrolled in Japan; ARCT-810 Phase 2 interim data expected later 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. reported the year ended December 31, 2022 results: revenue $206.0 million, net income approximately $9.3 million, EPS $0.35 per diluted share.

Period: the year ended December 31, 2022
Revenue: $206.0 million
Net income: approximately $9.3 million
EPS: $0.35 per diluted share
Result: reported results

Exact text from the filing

Total revenue for the year ended December 31, 2022, was $206.0 million compared with $12.4 million for the year ended December 31, 2021. The increase in fourth quarter and year-over-year revenues primarily relates to the $200 million upfront payment we received from the CSL transaction. Operating expenses : Total operating expenses for the three months ended December 31, 2022, were $38.8 million compared with $43.4 million for the three months ended December 31, 2021, and $50.2 million for the three months ended September 30, 2022. The decline in operating expenses when compared to the three months ended December 31, 2021, was primarily due to lower Covid-19 manufacturing and clinical related expenses. Total operating expenses for the year ended December 31, 2022, were $193.8 million compared with $215.2 million for the year ended December 31, 2021. Research and development expenses : Research and development expenses for the three months ended December 31, 2022, were $27.0 million com

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. reported the three months ended December 31, 2022 results: revenue $160.3 million, net income approximately $117.3 million, EPS $4.33 per diluted share.

Period: the three months ended December 31, 2022
Revenue: $160.3 million
Net income: approximately $117.3 million
EPS: $4.33 per diluted share
Result: reported results

Exact text from the filing

For the three months ended December 31, 2022, the Company reported revenue of $160.3 million compared with $5.8 million for the three months ended December 31, 2021, and $13.4 million for the three months ended September 30, 2022. Total revenue for the year ended December 31, 2022, was $206.0 million compared with $12.4 million for the year ended December 31, 2021. The increase in fourth quarter and year-over-year revenues primarily relates to the $200 million upfront payment we received from the CSL transaction. Operating expenses : Total operating expenses for the three months ended December 31, 2022, were $38.8 million compared with $43.4 million for the three months ended December 31, 2021, and $50.2 million for the three months ended September 30, 2022. The decline in operating expenses when compared to the three months ended December 31, 2021, was primarily due to lower Covid-19 manufacturing and clinical related expenses. Total operating expenses for the year ended December 31,

View on SEC.gov

Browse all earnings releases →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-23-000401

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.